SCHEMBL3883270

SCHEMBL3883270

Nc1nccc2c1ccn2-c1ccc(NC(=O)NC(=O)Cc2ccc(F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 16/20 0.49
▸ CYP3A4 P08684 5/20 0.49
▸ GAA P10253 2/20 0.43
▸ TP53 P04637 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ CSF1R P07333 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885800 0.91 MET (0.49) METCYP3A4GAATP53THRB
SCHEMBL5313559 0.86 TP53 (0.45) METCYP3A4TP53THRBROCK1
SCHEMBL3891463 0.82 MET (0.50) METCYP3A4GAATP53THRB
SCHEMBL13759627 0.80 MET (0.41) METCYP3A4TP53THRBCSF1R
SCHEMBL3886308 0.79 MET (0.48) METGAATP53THRBPDGFRA
Trifluoroacetic Acid SCHEMBL5313302 0.78 MET (0.46) METCYP3A4GAAROCK1CSF1R
SCHEMBL5313555 0.77 MLKL (0.40) METCYP3A4TP53THRBROCK1
SCHEMBL3885761 0.75 MET (0.60) METCYP3A4FLT3
SCHEMBL4069889 0.74 GAA (0.64) METCYP3A4GAASMN1; SMN2
SCHEMBL13759619 0.73 MET (0.45) METCYP3A4GAATP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742948-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-17 — — EP claimed
WO-2005116028-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-08 — — WO claimed
US-20050239820-A1 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-10-27 — — US claimed
US-7566784-B2 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-28 — — US disclosed
US-7566784-B2 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-28 — — US disclosed
US-7566784-B2 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-28 — — US disclosed
EP-1742948-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-17 — — EP disclosed
WO-2005116028-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-08 — — WO disclosed
US-20050239820-A1 Bicyclic heterocycles as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239820-A1 Bicyclic heterocycles as kinase inhibitors CDK2, ABL1, CDKN1A MET 610/4885CYP3A4 2044/4885GAA 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback